Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Celsion Corporation    CLSN

CELSION CORPORATION

(CLSN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/18/2020 09/21/2020 09/22/2020 09/23/2020 09/24/2020 Date
0.7895(c) 0.77(c) 0.7756(c) 0.7277(c) 0.7187(c) Last
1 202 539 653 839 433 342 419 270 527 667 Volume
-1.39% -2.47% +0.73% -6.18% -1.24% Change
More quotes
Financials (USD)
Sales 2020 0,51 M - -
Net income 2020 -19,8 M - -
Net Debt 2020 - - -
P/E ratio 2020 -1,09x
Yield 2020 -
Sales 2021 0,25 M - -
Net income 2021 -17,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,60x
Yield 2021 -
Capitalization 24,2 M 24,2 M -
Capi. / Sales 2020 47,9x
Capi. / Sales 2021 96,7x
Nbr of Employees 29
Free-Float 98,6%
More Financials
Company
Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid... 
More about the company
Notations Surperformance© of Celsion Corporation
Trading Rating : - Investor Rating :
More Ratings
All news about CELSION CORPORATION
09/08CELSION CORP : Entry into a Material Definitive Agreement, Other Events, Financi..
AQ
09/08CELSION : Announces Common Stock Purchase Agreement with Lincoln Park Capital an..
AQ
09/08Celsion Announces Common Stock Purchase Agreement with Lincoln Park Capital a..
GL
09/04CELSION CORP : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
09/02CELSION CORP : Entry into a Material Definitive Agreement, Termination of a Mate..
AQ
09/02Celsion Corporation Restructures its Strategic Loan Facility
GL
08/14CELSION : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
08/14CELSION CORP : Results of Operations and Financial Condition, Financial Statemen..
AQ
08/14Celsion Corporation Reports Second Quarter 2020 Financial Results and Provide..
GL
08/07Celsion Corporation to Hold Second Quarter 2020 Financial Results and Busines..
GL
08/04Celsion Corporation to Continue Following Patients in Phase III OPTIMA Study ..
GL
08/03CELSION CORP : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
07/27Celsion Corporation Initiates Phase II OVATION 2 Study of GEN-1 in Advanced O..
GL
07/14CELSION CORPORATION TO HOLD CONFEREN : 00 a.m. Eastern Time
GL
07/13CELSION CORP : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
More news
News in other languages on CELSION CORPORATION

- No features available -

More news
Chart CELSION CORPORATION
Duration : Period :
Celsion Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELSION CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 4,00 $
Last Close Price 0,73 $
Spread / Highest target 450%
Spread / Average Target 450%
Spread / Lowest Target 450%
EPS Revisions
Managers
NameTitle
Michael H. Tardugno Chairman, President & Chief Executive Officer
Jeffrey Wayne Church CFO, Secretary & SVP-Investor Relations
Nicholas Borys Chief Medical Officer & Senior Vice President
Khursheed Anwer Chief Scientific Officer & Executive VP
Pok Yu Chow Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CELSION CORPORATION-57.44%24
GILEAD SCIENCES, INC.-2.91%79 097
VERTEX PHARMACEUTICALS20.49%68 716
REGENERON PHARMACEUTICALS50.52%59 475
WUXI APPTEC CO., LTD.48.94%34 125
BEIGENE, LTD.65.71%24 830